Skip to content
NKCELLThe NK guide

Research & evidence

What Falls Under Immune Cell Therapy?

A clear guide to what counts as immune cell therapy, how it differs from other immunotherapy, and what two NK-cell study examples can—and cannot—show.

Immune cell therapy is the branch of immunotherapy that gives a patient living immune cells. It is not a synonym for every immunotherapy. A checkpoint inhibitor is a drug that releases a brake on the patient’s existing T cells; a CAR T-cell infusion supplies engineered T cells. Both are immunotherapy, but only the second is a cell therapy. That difference is the practical answer to what falls under the term: the product is made of cells, not just a molecule that changes immune behavior.

What counts as immunotherapy does not settle what counts as cell therapy

The National Cancer Institute’s overview separates immunotherapy from surgery, radiation, chemotherapy, targeted therapy and other cancer treatments. On its immunotherapy page, NCI groups immunotherapy into categories that include immune checkpoint inhibitors, T-cell transfer therapy, monoclonal antibodies, treatment vaccines and immune system modulators. These are not interchangeable. A category that is standard in one cancer setting does not automatically apply to an NK-cell infusion.

One cell-based example in NCI’s classification is T-cell transfer therapy. NCI describes it as a type of immunotherapy that helps a patient’s own T cells attack cancer, and it names tumor-infiltrating lymphocyte therapy and CAR T-cell therapy as the two main forms. CAR stands for chimeric antigen receptor—an engineered receptor that directs a T cell toward a chosen marker. Across cell therapies, the starting cells can be autologous (from the patient) or allogeneic (from a donor). Researchers often call this transfer of cells adoptive cell therapy.

NK cells—natural killer cells—are another immune cell type used in investigational cell therapy. But “NK cell therapy” is not a single product, and NCI’s cancer treatment overview does not list it as a general standard treatment. Its research questions depend on the product, the disease and the study design.

The research question changes with the cell product

For T-cell transfer, a central question is not merely whether T cells are present. It is whether the transferred cells recognize the intended target, persist in the body, reach the tumor and act without unacceptable toxicity. That is a general way to frame the problem; it is not a finding from the NCI page.

For NK-cell therapy, the cited examples show how specific those questions become. One ClinicalTrials.gov record, NCT07225439, describes a Phase I study combining rituximab, tafasitamab and allogeneic NK cells in people with relapsed or refractory B-cell non-Hodgkin lymphoma. “Relapsed or refractory” means the disease has come back after treatment or did not respond to it. Allogeneic means the cells come from a donor, not the patient. The record lists dose-limiting toxicity as the primary endpoint. A dose-limiting toxicity is a side effect severe enough to limit further dose increases. Phase I studies are early studies that usually focus on safety, dose and side effects; they are not designed to prove effectiveness. The record also describes the NK-cell component as investigational and not approved by the U.S. Food and Drug Administration. A Phase I design with that endpoint is asking a safety-first question; it does not show that the regimen works.

A second example comes from a 2020 early study on CAR-transduced natural killer cells in CD19-positive lymphoid tumors. CD19 is a marker found on some B-cell cancers. CAR-NK means NK cells engineered with a chimeric antigen receptor. The study involved 11 patients with relapsed or refractory disease and reported initial response and safety data for that specific CAR-NK product. It was small and non-confirmatory. It cannot be used to generalize to all CAR-NK therapies, all NK-cell infusions or all cancers.

Swipe or scroll to read the full table →

NK-cell example Disease and product What the source establishes What it does not establish
ClinicalTrials.gov record for one Phase I study Relapsed or refractory B-cell non-Hodgkin lymphoma; rituximab plus tafasitamab plus allogeneic NK cells The study phase, the primary endpoint of dose-limiting toxicity, and that the record describes the NK-cell component as investigational and not FDA approved That the regimen is effective or approved
2020 early study of CAR-transduced NK cells Relapsed or refractory CD19-positive lymphoid tumors; a specific CAR-NK product An early study in 11 patients that reported initial response and safety data for that product That all CAR-NK or NK-cell therapy works across cancers

Why the category matters

The category matters because it changes what evidence would be needed. A drug that modulates an existing immune response is tested differently from a living cell product that must be manufactured, transported and accepted by the recipient. For donor cells, researchers also have to ask whether the recipient’s immune system will reject the cells or whether the cells will attack normal tissue. Those are general cell-therapy questions, not results from the two NK examples.

The practical takeaway is narrower than the phrase might suggest. “Immune cell therapy” covers treatments built around living immune cells, such as T-cell transfer and investigational NK-cell approaches. It does not cover every immunotherapy, and one cell product’s early study does not establish a class-wide benefit. When a registry record says Phase I, it tells you the study’s main design question; when a small study reports initial data, it adds an early signal for that specific product. Neither is the same as proof for the whole category.

This is general educational information, not medical advice.

Sources and further reading

Keep reading

Follow the next question.

Research & evidence